Aerie pharmaceuticals reports fourth quarter and full year 2020 financial results and provides business update

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq:aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the fourth quarter and year ended december 31, 2020 and provided a general business update. “our fourth quarter 2020 net revenues of $24.7 million exceeded third
AERI Ratings Summary
AERI Quant Ranking